account adjust acquisition-rel cost certain
signific item
revenu ep ahead estim top bottom line guidanc increas
ep ahead estim consensu
ep guidanc rais prior fx impact estim
vs prior last publish ep estim
sale estim
consensu product beat estim includ keytruda
januvia gardasil simponi zetia singulair cubicin isentress remicad
vytorin combin forecast product forecast includ
zepati light zostavax combin light
anim sale estim sale guidanc increas
prior includ fx impact vs prior last
publish revenu estim believ lt revenu growth
potenti underappreci consenu peg revenu growth
gpm estim
estim sg estim net non-oper
incom forecast includ litig settlement
ad ep tax rate estim share count
forecast
keytruda full ph data monotherapi nsclc met os
ph ii/iii data squamou nsclc
ph ii data rcc approv primari
nsclc w/alimta chemo pdufa scchn confirmatori
pdufa keytruda epacadostat full ph data melanoma miss
januvia next step post apr label inclus teco data doravirin
 approv hiv mono tablet fdc lamivudin tenofovir pdufa
lynparza w/azn ph data regulatori file brcam
ovarian cancer ph data pancreat cancer japan approv
eu approv ovarian cancer posit chmp feb zerbaxa ph data vabp
relebactem w/imipenem cilastin file imipenem non-suscept infect
pleas see page report import disclosur
merck competit posit line lung cancer clear posit merck face
uncertainti includ januvia outlook competit market remicad zetia
vytorin cubicin nasonex biosimilars/gener competit pressur isentress
zostavax believ risk balanc opportun therefor remain market
perform stock
uptak keytruda nsclc
keytruda data readout variou tumor
keytruda approv b-cell
chemo scchn
lynparza data/fil ovarian
oper margin improv
keytruda data and/or uptak lung
posit expect
new product unabl off-set nasonex
vytorin/zetia cubicin patent
expir competit pressur
zostavax isentress
merck global health care compani includ prescript medicin vaccin
biolog therapi anim health strong product presenc oncolog
cardiovascular anti-infect anti-inflammatori diabet area among other
anim health divis focus mainli feed anim
cowen compani
cowen compani compani data
cowen compani
cowen compani
cowen compani
m-m-r ii cowen
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio market cap/fre cash flow metric
failur pipelin product intellectu properti challeng econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
risk includ continu success exist portfolio notabl januvia vytorin
zetia isentress success pipelin product especi suvorex odanacatib
anacetrapib lambrolizumab success deal patent litig patent
expir pressur binari risk includ safeti issu involv odanacatib
improve-it studi vytorin
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock merck secur
author report member author household long posit equiti secur merck
author report member author household long posit equiti secur
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
